Zura Bio reported a Phase 2 failure for tibulizumab in hidradenitis suppurativa, with both evaluated doses failing to outperform placebo on the primary symptoms outcome. The company’s stock sold off after the setback, reflecting investor sensitivity to mid-stage readouts in competitive, hard-to-treat inflammatory indications. For Zura, the result narrows near-term options for the program and raises pressure to provide a clearer development path—either through revised endpoints, next-line patient selection, or re-scoping of the immunology strategy.